Renee D. Gala, President and Chief Executive Officer of Jazz Pharmaceuticals plc (NASDAQ:JAZZ), filed a Form 4 on September 10, 2026, disclosing two transactions in ordinary shares dated September 8, 2026.

Key Highlights

  • Tax withholding: 1,967 ordinary shares were disposed of at $246.81 per share to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
  • Planned sale: 2,000 ordinary shares were sold at $243.03 per share under a Rule 10b5-1 plan adopted by the reporting person on June 4, 2026.
  • Automatic execution: According to the filing, the sale "occurred automatically and does not represent a discretionary transaction by the reporting person."
  • Resulting ownership: Following both transactions, Gala directly beneficially owned 143,394 ordinary shares.
  • Both transactions direct: All shares reported are held in direct ownership form.

Transaction Details for Jazz Pharmaceuticals CEO Renee D. Gala

According to the Form 4 filed with the SEC on September 10, 2026, Renee D. Gala, serving as President and Chief Executive Officer of Jazz Pharmaceuticals plc, reported two transactions in the company's ordinary shares, both occurring on September 8, 2026. The filing was signed by Paz Dizon as attorney in fact for Gala.

The first transaction, coded "F," involved the disposal of 1,967 ordinary shares at a price of $246.81 per share. The filing states this represented shares withheld to satisfy tax obligations arising from the vesting of a portion of previously granted restricted stock units. Following this transaction, Gala's direct beneficial ownership stood at 145,394 ordinary shares.

The second transaction, coded "S," involved the sale of 2,000 ordinary shares at $243.03 per share. The filing discloses that this sale was made pursuant to a Rule 10b5-1 plan that Gala adopted on June 4, 2026. After this sale, direct beneficial ownership was reduced to 143,394 ordinary shares. The filing also indicates that the form was checked to reflect a transaction made pursuant to a contract, instruction, or written plan satisfying the affirmative defense conditions of Rule 10b5-1(c).

What Was Disclosed

The filing disclosed two disposals of Jazz Pharmaceuticals ordinary shares by its President and CEO on September 8, 2026: a tax-related withholding of 1,967 shares at $246.81 and a planned sale of 2,000 shares at $243.03, leaving direct beneficial ownership of 143,394 shares.